Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Forecast

Key Highlights

• DelveInsight's analysist projects that in 2023, there were approximately 13.3 thousand diagnosed prevalent cases of CIDP in the EU4 and the UK. This number is expected to grow at a compound annual growth rate (CAGR) of 0.4%.
• The prevalence of CIDP is expected to rise due to an aging population, enhanced diagnostic methods, and increased awareness among healthcare professionals. These factors enable earlier and more accurate detection. Additionally, advancements in medical research may identify previously overlooked cases, contributing to the growing number of reported instances.
• The US accounted for nearly 30.2 thousand diagnosed prevalent cases of CIDP in 2023. This figure is anticipated to grow at a compound annual growth rate (CAGR) of 0.7% by 2034.
• In 2023, Germany reported approximately 2,300 CIDP cases among males and around 800 cases among females. 
• The EU4 and the UK recorded about 2.2 thousand refractory CIDP cases in 2023.
• In 2023, the diagnosed prevalent cases of CIDP across the age groups 0–19 years, 20–39 years, 40–59 years, 60-79 years, and 80 years and above were approximately 40, 80, 800, 900 and 200, respectively, in Japan. 

DelveInsight’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CIDP, historical and forecasted epidemiology of CIDP in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Disease Understanding 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

CIDP is the most common autoimmune polyneuropathy, affecting the peripheral nervous system. This rare and complex condition is marked by inflammation and demyelination of peripheral nerves, resulting in progressive muscle weakness, sensory loss, and motor difficulties. CIDP can significantly impact an individual's daily life and mobility. Symptoms like weakness, sensory impairment, paresthesia, and areflexia are key for diagnosing and managing the disease. Early detection is crucial for distinguishing CIDP from other neuropathies and allows for timely treatment. Monitoring symptoms over time helps track disease progression and optimize therapeutic approaches.

Diagnosing Chronic CIDP involves a clinical assessment to identify symptoms such as muscle weakness and sensory loss. Nerve conduction studies (NCS) are used to detect slowed nerve conduction. Cerebrospinal fluid (CSF) analysis may show elevated protein levels. Electromyography (EMG) is performed to rule out other possible conditions. Additionally, imaging methods like MRI and ultrasound are employed to aid in the diagnosis and differentiate CIDP from similar disorders. These diagnostic tools work together to provide a comprehensive evaluation, helping to confirm CIDP and guide appropriate treatment decisions.

Further details related to diagnosis are provided in the report…

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

For the purpose of designing the patient-based model for CIDP, the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of CIDP, Gender-specific Diagnosed Prevalent Cases of CIDP, Age-specific Diagnosed Prevalent Cases of CIDP, Clinical Subtype-specific Diagnosed Prevalent Cases of CIDP, and Refractory Cases of CIDP in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, from 2021 to 2034. 

• DelveInsight's epidemiology model estimates that in 2023, there were approximately 45 thousand diagnosed prevalent cases of CIDP across the 7MM which are expected to increase by 2034.
• In 2023, the US reported the highest number of diagnosed prevalent cases of CIDP among the 7MM, with approximately 30 thousand, a figure expected to rise by 2034.
• In 2023, among the Subtype-specific diagnosed prevalent cases of CIDP in the Japan, typical CIDP accounted for approximately 1200 cases, and atypical CIDP for nearly 800 cases.
• In 2023, the diagnosed prevalent cases of CIDP across the age groups 0–19 years, 20–39 years, 40–59 years, 60–79 years, and 80 years and above were approximately 80, 80, 800, 1,800 and 500, respectively, in Germany.
• In 2023, France had approximately 2,200 males and 740 females diagnosed with CIDP and these number is expected to increase by 2034.
• In 2023, the UK recorded around 530 refractory cases of CIDP patients among the 7MM.
• In 2023, in Spain, around 82% of CIDP cases were classified as typical CIDP, while 18% are atypical CIDP. This indicates that typical CIDP is more prevalent than atypical CIDP in the country.
• In 2023, Italy reported the 2.2 thousand diagnosed prevalent cases of CIDP among the 7MM.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence. 

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Minnesota, the US, University Hospital of Leicester, the US, Thomas Jefferson University, the US, University Hospital Cologne,  Germany, Centre Hospitalier Universitaire (CHU) de Saint-Étienne, France, Università degli Studi del Piemonte Orientale, Italy,  Hospital de la Santa Creu i Sant Pau, Spain, University College London, the UK, Kindai University, Japan among others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

As per the KOLs from the US, it is becoming increasingly evident that a significant number of patients diagnosed with CIDP may actually have a different underlying condition, or in some cases, no neuropathy at all. Studies suggest that up to half of those diagnosed in the US may be misdiagnosed, highlighting the need for more accurate diagnostic practices.

As per the KOLs from the Italy, the epidemiological characteristics of CIDP presents significant challenges. The rarity of the disorder means large populations are needed for accurate data. Additionally, the lack of a universally accepted diagnostic gold standard and the complexity of existing criteria complicate diagnosis. Furthermore, the clinical boundaries of CIDP remain unclear, as several comorbidities are associated with the condition, but their pathogenic roles have yet to be fully understood. These factors make epidemiological studies of CIDP particularly difficult.

As per the KOLs from Japan, CIDP is an immune-mediated condition that leads to gradual peripheral nerve damage over a period of two months or longer. Due to its slow progression, CIDP demands careful diagnosis and management. Understanding its epidemiology is essential for enhancing patient outcomes and better addressing the condition in the region.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of CIDP, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Chronic Inflammatory Demyelinating Polyneuropathy Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Diagnosed Prevalent Cases of CIDP
• Gender-specific Diagnosed Prevalent Cases of CIDP
• Age-specific Diagnosed Prevalent Cases of CIDP
• Clinical Subtype-specific Diagnosed Prevalent Cases of CIDP
• Refractory Cases of CIDP

Chronic Inflammatory Demyelinating Polyneuropathy Report Key Strengths

• 10 years Forecast
• The 7MM Coverage 
• CIDP Epidemiology Segmentation 

Chronic Inflammatory Demyelinating Polyneuropathy Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of CIDP? What will be the growth opportunities across the 7MM concerning the patient population of CIDP?
• What is the historical and forecasted CIDP patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why are the total cases of CIDP in Japan lower than in the US?
• Which country has a high patient share for CIDP?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the CIDP cases in varying geographies over the coming years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The CIDP Epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of CIDP cases in 2023?

The highest cases of CIDP were found in the United Kingdom among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of CIDP cases in 2023?

The highest cases of CIDP were found in the US among the 7MM in 2023.